Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 22
Filter
1.
J Adv Nurs ; 79(6): 2316-2327, 2023 Jun.
Article in English | MEDLINE | ID: mdl-36779456

ABSTRACT

AIM: To examine the mediating effect of sleep quality on the relationship between lower urinary tract symptoms and health-related quality of life in women with type-II diabetes. DESIGN: A cross-sectional study. METHODS: A study questionnaire comprising three valid instruments was used to obtain data about lower urinary tract symptoms, sleep quality and physical and mental component summary health-related quality of life between July 2017 and December 2018 (n = 343). Pearson's correlation coefficients were estimated initially to examine the relationships between the three variables. Multiple regression models were tested using a regression-based approach Hayes PROCESS macro for SPSS to examine the significance of proposed mediation effects. RESULTS: Most participants experienced at least one urinary symptom (n = 268, 78.1%). The total number of types of lower urinary tract symptoms experienced by participants was significantly inversely correlated with physical and mental component summary health-related quality of life, and sleep quality. Participants' sleep quality was significantly correlated with physical and mental component summary health-related quality of life. The relationships of lower urinary tract symptoms with physical and mental component summary health-related quality of life were, respectively, fully and partially mediated by sleep quality. CONCLUSION: Sleep quality played a mediating role on the relationship between lower urinary tract symptoms and health-related quality of life. Our findings could lead to improvements of diabetes care in nursing and healthcare practices. IMPACT: Understanding the role of sleep quality in the adverse effects of lower urinary tract symptoms on health-related quality of life contributes to the development and delivery of appropriate strategies to promote optimal health-related quality of life. We recommended including assessments of lower urinary tract symptoms, sleep and health-related quality of life in routine diabetes management. Nurses and healthcare professionals should concurrently reduce lower urinary tract symptoms and improve sleep to achieve this population's optimal health-related quality of life. PATIENTS OR PUBLIC CONTRIBUTION: We recruited a sample of older women with type-II diabetes at the endocrinology and metabolism outpatient departments of two hospitals. Study participants provided responses on the study questionnaires. The two hospitals provided needed supports (e.g., height/weight scales, suitable places for interview) during the data collection process.


Subject(s)
Diabetes Mellitus, Type 2 , Lower Urinary Tract Symptoms , Humans , Female , Aged , Quality of Life , Sleep Quality , Cross-Sectional Studies , Diabetes Mellitus, Type 2/complications , Surveys and Questionnaires
2.
Article in English | MEDLINE | ID: mdl-36497716

ABSTRACT

BACKGROUND: Urinary incontinence (UI) and poor sleep negatively affect health-related quality of life (HRQoL). This study explored the UI-related factors and the relationships between UI, sleep quality, and HRQoL. METHODS: This cross-sectional study collected data from 237 women with type 2 diabetes. Multivariate logistic regression was conducted to identify the factors associated with UI. One-way analysis of variance was used to compare the mean sleep quality and HRQoL scores of women without UI and those who experienced UI of varying severities. Correlation coefficients were estimated, and multivariate linear regression was conducted to examine the relationships between UI severity, sleep quality, and HRQoL. RESULTS: Of the 237 women, 115 (48.52%) experienced UI and 139 (58.65%) were poor sleepers. The three factors associated with UI were advanced age, a higher body mass index, and a history of vaginal delivery. Significant associations between UI severity and sleep quality and between sleep quality and HRQoL were revealed. UI severity and night-time voiding frequency were both associated with sleep quality. CONCLUSIONS: One factor associated with UI (body mass index) is modifiable. UI severity is associated with sleep quality as the possible influence of night-time voiding frequency on sleep quality has been considered.


Subject(s)
Diabetes Mellitus, Type 2 , Urinary Incontinence , Humans , Female , Aged , Cross-Sectional Studies , Quality of Life , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/epidemiology , Sleep Quality , Urinary Incontinence/epidemiology , Surveys and Questionnaires , Prevalence
3.
Sci Rep ; 9(1): 9919, 2019 07 09.
Article in English | MEDLINE | ID: mdl-31289326

ABSTRACT

The signaling mechanisms controlling somatic cell reprogramming are not fully understood. In this study, we report a novel role for mitochondrial Akt1 signaling that enhanced somatic cell reprogramming efficiency. The role of mitochondrial Akt1 in somatic cell reprogramming was investigated by transducing fibroblasts with the four reprogramming factors (Oct4, Sox2, Klf4, c-Myc) in conjunction with Mito-Akt1, Mito-dnAkt1, or control virus. Mito-Akt1 enhanced reprogramming efficiency whereas Mito-dnAkt1 inhibited reprogramming. The resulting iPSCs formed embryoid bodies in vitro and teratomas in vivo. Moreover, Oct4 and Nanog promoter methylation was reduced in the iPSCs generated in the presence of Mito-Akt1. Akt1 was activated and translocated into mitochondria after growth factor stimulation in embryonic stem cells (ESCs). To study the effect of mitochondrial Akt in ESCs, a mitochondria-targeting constitutively active Akt1 (Mito-Akt1) was expressed in ESCs. Gene expression profiling showed upregulation of genes that promote stem cell proliferation and survival and down-regulation of genes that promote differentiation. Analysis of cellular respiration indicated similar metabolic profile in the resulting iPSCs and ESCs, suggesting comparable bioenergetics. These findings showed that activation of mitochondrial Akt1 signaling was required during somatic cell reprogramming.


Subject(s)
Cell Differentiation , Cellular Reprogramming , Embryonic Stem Cells/cytology , Induced Pluripotent Stem Cells/cytology , Proto-Oncogene Proteins c-akt/metabolism , Animals , Cells, Cultured , Embryonic Stem Cells/metabolism , Humans , Induced Pluripotent Stem Cells/metabolism , Kruppel-Like Factor 4 , Mice , Mice, Inbred C57BL , Signal Transduction , Transcriptional Activation
4.
J Nurs Scholarsh ; 49(4): 400-410, 2017 07.
Article in English | MEDLINE | ID: mdl-28544465

ABSTRACT

PURPOSES: To explore correlates of nocturia, compare sleep quality and glycemic control for women with and without nocturia, and examine relationships of nocturia with sleep quality and glycemic control in women with diabetes. DESIGN: This study was a cross-sectional, correlational study with data collected from 275 women with type 2 diabetes. METHODS: Data were collected using a structured questionnaire. Multivariate logistic regression analyses were used to identify correlates. Chi-squared tests were used to identify candidate variables for the first logistic regression model. A one-way analysis of variance was used to compare sleep quality and glycemic control for women with and those without nocturia. Pearson correlations were used to examine the relationships of nocturia with sleep quality and glycemic control. FINDINGS: Of the 275 participants, 124 (45.1%) had experienced nocturia (at least two voids per night). Waist circumference, parity, time since diagnosis of diabetes, sleep quality, and increased daytime urinary frequency were correlated with nocturia after adjusting for age. Compared to women without nocturia, women who had nocturia reported poorer sleep quality. A significant correlation was found between the number of nocturnal episodes and sleep quality. CONCLUSIONS: Nocturia and poor sleep are common among women with diabetes. The multifactorial nature of nocturia supports the delivered management and treatments being targeted to underlying etiologies in order to optimize women's symptom management. Interventions aimed at modifiable correlates may include maintaining a normal body weight and regular physical exercise for maintaining a normal waist circumference, and decreasing caffeine consumption, implementing feasible modifications in sleeping environments and maintaining sleep hygiene to improve sleep quality. CLINICAL RELEVANCE: Healthcare professionals should screen for nocturia and poor sleep and offer appropriate nonpharmacological lifestyle management, behavioral interventions, or pharmacotherapy for women with diabetes.


Subject(s)
Blood Glucose/metabolism , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/physiopathology , Nocturia/epidemiology , Sleep/physiology , Adult , Aged , Cross-Sectional Studies , Diabetes Mellitus, Type 2/epidemiology , Female , Humans , Middle Aged , Risk Factors , Surveys and Questionnaires , Young Adult
5.
Int J Mol Sci ; 16(3): 5789-802, 2015 Mar 12.
Article in English | MEDLINE | ID: mdl-25775159

ABSTRACT

Ultraviolet radiation, especially UVA, can penetrate the lens, reach the retina, and induce oxidative stress to retinal pigment epithelial (RPE) cells. Even though it is weakly absorbed by protein and DNA, it may trigger the production of reactive oxygen species (ROS) and generate oxidative injury; oxidative injury to the retinal pigment epithelium has been implicated to play a contributory role in age-related macular degeneration (AMD). Studies showed that resveratrol, an abundant and active component of red grapes, can protect several cell types from oxidative stress. In this study, adult RPE cells being treated with different concentrations of resveratrol were used to evaluate the protective effect of resveratrol on RPE cells against UVA-induced damage. Cell viability assay showed that resveratrol reduced the UVA-induced decrease in RPE cell viability. Through flow cytometry analysis, we found that the generation of intracellular H2O2 induced by UVA irradiation in RPE cells could be suppressed by resveratrol in a concentration-dependent manner. Results of Western blot analysis demonstrated that resveratrol lowered the activation of UVA-induced extracellular signal-regulated kinase, c-jun-NH2 terminal kinase and p38 kinase in RPE cells. In addition, there was also a reduction in UVA-induced cyclooxygenase-2 (COX-2) expression in RPE cells pretreated with resveratrol. Our observations suggest that resveratrol is effective in preventing RPE cells from being damaged by UVA radiation, and is worth considering for further development as a chemoprotective agent for the prevention of early AMD.


Subject(s)
Cell Survival/drug effects , Stilbenes/pharmacology , Ultraviolet Rays , Cell Line , Cell Survival/radiation effects , Cyclooxygenase 2/metabolism , Extracellular Signal-Regulated MAP Kinases/metabolism , Humans , Hydrogen Peroxide/metabolism , JNK Mitogen-Activated Protein Kinases/metabolism , Oxidative Stress/drug effects , Oxidative Stress/radiation effects , Phosphorylation/drug effects , Phosphorylation/radiation effects , Radiation-Protective Agents/pharmacology , Resveratrol , Retinal Pigment Epithelium/cytology , Retinal Pigment Epithelium/metabolism , p38 Mitogen-Activated Protein Kinases/metabolism
6.
Prim Care Diabetes ; 9(2): 135-41, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25266893

ABSTRACT

AIMS: Factors predicting success (glycosylated hemoglobin (A1C)<7%) with insulin therapy in patients with insulin-requiring type 2 diabetes need to be identified. METHODS: A retrospective, multi-center, observational study was conducted for outpatients with oral antidiabetic drug (OAD)-treated type 2 diabetes whose A1C levels remained above 7%. Patients were begun on basal insulin between January 2005 and December 2006. Biochemical variables and demographic data were collected before and after 52 weeks of insulin therapy. RESULTS: A total of 565 patients (age, 60.4±11.9 years; A1C levels, 10.11 ±1.81%; duration of diabetes, 11.5±6.8 years) were studied. By study end, 63 patients (11.2%) had achieved the glycemic goal (A1C<7%). The glycemic goal attainment rate was only 9.1% in patients with A1C>8.8% and who were taking >2 OADs at baseline. The highest rate (32.7%) of successful glycemic control was observed in the group of patients with A1C ≤ 8.8% and who used ≤ 2 OADs at baseline. CONCLUSIONS: Insulin-naïve diabetic patients with A1C>8.8%, especially those who are taking >2 OADs, have small chance to achieve good glycemic control with adding only basal insulin therapy.


Subject(s)
Blood Glucose/drug effects , Diabetes Mellitus, Type 2/drug therapy , Glycated Hemoglobin/metabolism , Hypoglycemic Agents/administration & dosage , Insulin/administration & dosage , Administration, Oral , Aged , Biomarkers/blood , Blood Glucose/metabolism , Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/diagnosis , Drug Therapy, Combination , Female , Humans , Male , Middle Aged , Retrospective Studies , Taiwan , Time Factors , Treatment Outcome
7.
Int J Mol Sci ; 15(8): 13755-67, 2014 Aug 08.
Article in English | MEDLINE | ID: mdl-25110866

ABSTRACT

During the course of proliferative vitreoretinopathy (PVR), the retinal pigment epithelium (RPE) cells will de-differentiate, proliferate, and migrate onto the surfaces of the sensory retina. Several studies have shown that platelet-derived growth factor (PDGF) can induce migration of RPE cells via an Akt-related pathway. In this study, the effect of lutein on PDGF-BB-induced RPE cells migration was examined using transwell migration assays and Western blot analyses. We found that both phosphorylation of Akt and mitochondrial translocation of Akt in RPE cells induced by PDGF-BB stimulation were suppressed by lutein. Furthermore, the increased migration observed in RPE cells with overexpressed mitochondrial Akt could also be suppressed by lutein. Our results demonstrate that lutein can inhibit PDGF-BB induced RPE cells migration through the inhibition of both cytoplasmic and mitochondrial Akt activation.


Subject(s)
Cell Movement/drug effects , Cytosol/metabolism , Lutein/pharmacology , Mitochondria/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Becaplermin , Cell Line , Humans , Mitochondria/drug effects , Proto-Oncogene Proteins c-akt/genetics , Proto-Oncogene Proteins c-sis/pharmacology , Retinal Pigment Epithelium/cytology , Retinal Pigment Epithelium/drug effects , Retinal Pigment Epithelium/metabolism , Signal Transduction/drug effects
8.
Clin Chim Acta ; 435: 18-23, 2014 Aug 05.
Article in English | MEDLINE | ID: mdl-24721640

ABSTRACT

BACKGROUND: Apelin regulates insulin sensitivity and secretion in animals. However, whether plasma apelin predicts incident diabetes in humans remains unknown. METHODS: We studied a cohort including 447 subjects (148 men, 299 women) without diabetes and followed for an average of 3y. Diabetes was diagnosed by an oral glucose tolerance test, plasma hemoglobin A1c, and if the subject was taking medications for diabetes. Plasma apelin-12 at baseline was measured with a commercial kit. RESULTS: Plasma apelin concentrations were higher in women than in men at baseline (p=0.007). During follow-up, 43 subjects developed type 2 diabetes. Higher plasma apelin concentrations were associated with a higher risk of diabetes in men (p=0.049) but not in women. Plasma apelin predicted incident type 2 diabetes in men (hazard ratio, 2.13, 95% CI 1.29-3.51, p<0.05), but not in women, adjusted for age, family history of diabetes, hemoglobin A1c, body mass index, hypertension, and HOMA2-IR. Apelin could improve the prediction ability beyond traditional risk factors in men, and the sensitivity and specificity of plasma apelin at 0.9ng/ml for this prediction were 63.2% and 58.9%, respectively. In men at risk for diabetes (HbA1c 5.7-6.4%, FPG 100-125mg/dl, or OGTT-2h-PG 140-199mg/dl), the risk for developing diabetes was higher in those with higher plasma apelin concentration than in those with lower plasma apelin concentrations (10.6%/year vs. 5.1%/year, p<0.001). CONCLUSIONS: Plasma apelin is a novel biomarker for predicting type 2 diabetes in men.


Subject(s)
Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/diagnosis , Intercellular Signaling Peptides and Proteins/blood , Adult , Aged , Aged, 80 and over , Apelin , Biomarkers/blood , Female , Humans , Male , Middle Aged , Risk Factors , Sex Factors , Young Adult
9.
Psychosom Med ; 75(1): 30-5, 2013 Jan.
Article in English | MEDLINE | ID: mdl-23107841

ABSTRACT

OBJECTIVE: The aim of the present study was to investigate the association between panic disorder (PD) and atrial fibrillation (AF). METHODS: We used a nationwide population-based data set from Taiwan. A total of 3888 patients with PD and without a diagnosis of AF from a sampled cohort data set of 1,000,000 were included in the study group. Ten people without PD and AF were selected for every 1 patient in the study group, matched by propensity score matching according to time of enrollment, age, sex, and comorbidities. We performed log-rank tests to analyze differences in accumulated AF-free survival rates between the two groups. Cox proportional hazard regressions were performed to evaluate the independent factors determining the longitudinal hazard of AF. RESULTS: During a maximal 7-year follow-up, 48 patients from the study group (1.2% of the patients with PD) and 358 from the control group (0.9% of the patients without PD) were newly diagnosed as having AF. Patients with PD had a significantly higher incidence of AF (hazard ratio [HR] = 1.54 [1.14-2.09]; log-rank test, p = .004). After Cox model adjustment for risk factors and comorbidities, PD (HR = 1.73, 95% confidence interval [CI] = 1.26-2.37), age (HR = 1.07, 95% CI = 1.06-1.08), male sex (HR = 1.26, 95% CI = 1.03-1.55), hypertension (HR = 2.00, 95% CI = 1.55-2.56), history of coronary artery disease (HR = 1.45, 95% CI = 1.15-1.82), congestive heart failure (HR = 2.46; 95% CI, 1.84-3.30), and valvular heart disease (HR = 2.83, 95% CI = 1.85-4.42) were independently associated with increased risk of AF. CONCLUSIONS: PD is independently associated with higher incidence of AF to be diagnosed in the future. Larger prospective studies or meta-analysis are suggested to confirm the findings.


Subject(s)
Atrial Fibrillation/psychology , Panic Disorder/psychology , Adult , Age Factors , Atrial Fibrillation/epidemiology , Coronary Artery Disease/epidemiology , Disease-Free Survival , Epidemiologic Methods , Female , Heart Valve Diseases/epidemiology , Humans , Hypertension/epidemiology , Male , Middle Aged , Panic Disorder/epidemiology , Sex Factors , Taiwan/epidemiology
10.
J Diabetes Complications ; 26(4): 296-300, 2012.
Article in English | MEDLINE | ID: mdl-22626873

ABSTRACT

BACKGROUND: To evaluate the relationship between hemoglobin A1c variability and all-cause mortality in type 2 diabetic patients. METHODS: This was a retrospective cohort study in type 2 diabetic patients followed for at least 2 years between 2003 and 2009. A1C variability was determined from the standard deviation or coefficient of variation of serial A1C values (A1C(SD) or A1C(CV)). Subjects were categorized into either the high or low A1C variability group according to their A1C(CV) median. Hazard ratios (HRs) of various factors for all-cause mortality were determined from Cox's proportional hazard models. RESULTS: A total of 881 subjects (422 men, 459 women) were included and 73 (8.3%) died during follow-up. The follow-up period was 4.7 ± 2.3 years. All-cause mortality was higher in subjects with high A1C(CV) (11.0% vs. 5.4%, p=0.002). In the Kaplan-Meier failure curve, subjects with higher A1C(CV) demonstrated a trend of higher mortality (p=0.1). In multivariate Cox's proportional hazards models, A1C(SD) and A1C(CV) significantly predicted all-cause mortality with an HR of 1.987 (p=0.02) and 1.062 (p=0.013), respectively, after adjusting for age, gender, body mass index, duration of diabetes, mean systolic blood pressure, use of antihypertensives and statins, mean LDL-cholesterol, smoking status, chronic kidney disease, and mean A1C values (A1C(MEAN)). The ability of A1C(SD) and A1C(CV) to predict all-cause mortality was more evident in subjects with relatively low A1C(MEAN.) CONCLUSIONS: A1C variability is an important risk factor for all-cause mortality in type 2 diabetic patients.


Subject(s)
Diabetes Mellitus, Type 2/blood , Diabetes Mellitus, Type 2/mortality , Glycated Hemoglobin/metabolism , Aged , Cohort Studies , Female , Follow-Up Studies , Humans , Kaplan-Meier Estimate , Male , Middle Aged , Predictive Value of Tests , Proportional Hazards Models , Retrospective Studies , Risk Factors
11.
Am J Physiol Heart Circ Physiol ; 302(3): H716-23, 2012 Feb 01.
Article in English | MEDLINE | ID: mdl-22081709

ABSTRACT

We recently reported translocation and activation of Akt in cardiac mitochondria. This study was to determine whether activation of Akt in mitochondria could inhibit apoptosis of cardiac muscle cells. Insulin stimulation induced translocation of phosphorylated Akt to the mitochondria in primary cardiomyocytes. A mitochondria-targeted constitutively active Akt was overexpressed via adenoviral vector and inhibited efflux of cytochrome c and apoptosis-inducing factor from mitochondria to cytosol and partially prevented loss of mitochondria cross-membrane electrochemical gradient. Activation of caspase 3 was suppressed in the cardiomyocytes transduced with mitochondria-targeted active Akt, whereas a mitochondria-targeted dominant negative Akt enhanced activation of caspase 3. Terminal deoxynucleotidyl transferase dUTP-mediated nick-end labeling assay showed that mitochondrial activation of Akt significantly reduced the number of apoptotic cells. When the endogenous Akt was abolished by LY294002, the antiapoptotic actions of mitochondrial Akt remained effective. These experiments suggested that mitochondrial Akt suppressed apoptosis signaling independent of cytosolic Akt in cardiac muscle cells.


Subject(s)
Apoptosis/physiology , Mitochondria/metabolism , Myocytes, Cardiac/metabolism , Proto-Oncogene Proteins c-akt/metabolism , Signal Transduction/physiology , Animals , Apoptosis/drug effects , Caspase 3/metabolism , Cell Nucleus/metabolism , Chromones/pharmacology , Cytosol/metabolism , Enzyme Inhibitors/pharmacology , Membrane Potential, Mitochondrial/physiology , Morpholines/pharmacology , Mutagenesis/physiology , Myocytes, Cardiac/cytology , Primary Cell Culture , Proto-Oncogene Proteins c-akt/genetics , Rats , Rats, Sprague-Dawley
12.
Clin Chim Acta ; 412(7-8): 583-6, 2011 Mar 18.
Article in English | MEDLINE | ID: mdl-21172335

ABSTRACT

BACKGROUND: Glycated albumin (GA) may contribute to diabetic nephropathy, but the clinical significance of GA in patients with chronic kidney disease (CKD) is unknown. METHODS: Patients were classified with the NKF/DOQI classification system as mild (stage I, II), moderate (stage III), or advanced CKD (stage IV). Those undergoing dialysis or with CKD stage V were excluded. GA was measured using the Lucica TM GA-L assay kit. The relationship between GA and renal dysfunction was analyzed in patients with or without diabetes. RESULTS: A total of 187 subjects were enrolled. GA values in those with normal, mild, moderate and advanced CKD were 18.4 ± 1.4%, 18.4 ± 3.1%, 19.0 ± 3.8%, 20.4 ± 6.4%, respectively, in diabetic patients (N=67, p=0.5), and were 14.1 ± 1.9%, 14.2 ± 2.2%, 15.9 ± 1.9%, 15.0 ± 1.7%, respectively, in nondiabetic patients (N=120, p=0.004). GA value was negatively correlated to eGFR in nondiabetic patients (r=-0.35, p<0.001) but not in diabetic patients (r=-0.11, p=0.39). In the adjusted model, GA is independently correlated to eGFR only in nondiabetic subjects. CONCLUSIONS: Increased GA concentrations are independently associated with renal dysfunction in nondiabetic patients with CKD.


Subject(s)
Glomerular Filtration Rate , Renal Insufficiency, Chronic/blood , Serum Albumin/analysis , Female , Glycosylation , Humans , Male , Middle Aged
13.
Ann Acad Med Singap ; 39(1): 4-8, 2010 Jan.
Article in English | MEDLINE | ID: mdl-20126806

ABSTRACT

INTRODUCTION: There is no single method of measuring insulin resistance that is both accurate and can be easily performed by general researchers. We validate the accuracy of oral glucose insulin sensitivity (OGIS) in the Chinese by comparing the OGIS120 and OGIS180, homeostasis model assessment of insulin resistance (HOMA-IR), and quantitative insulin sensitivity check index (OUICKI) with steady-state plasma glucose (SSPG) in different glucose tolerance subjects. MATERIALS AND METHODS: We enrolled 515 subjects, aged between 20 and 75 years old, during routine health evaluations. All subjects were divided into normal, obese, impaired fasting glucose (IFG), impaired glucose tolerance (IGT) and type 2 diabetes (T2D) groups. Participants had a 3-hour oral glucose tolerance test (OGTT) and SSPG with an insulin suppression test. The relationships between SSPG and OGIS120, OGIS180, HOMA-IR, and QUICKI were evaluated. RESULTS: The normal group had the highest OGIS120, OGIS180 and lowest SSPG as compared with the other 4 groups. OGIS180, HOMA-IR and QUICKI in all 5 groups were significantly related to SSPG (r = 0.397-0.621, all P <0.05). OGIS120 in all 5 groups was not significantly related to SSPG (r = 0.003-0.226). Additionally, the r value of OGIS180 against SSPG was not higher than the other 2 insulin sensitivity surrogates from OGTT. CONCLUSIONS: Although OGIS180 was more accurate in estimating insulin sensitivity than OGIS120 in the Chinese, it was not superior to the traditional surrogates such as HOMA-IR or QUICKI.


Subject(s)
Glucose Tolerance Test/methods , Insulin Resistance , Prediabetic State/diagnosis , Adult , Aged , Case-Control Studies , China , Female , Humans , Male , Middle Aged , Young Adult
14.
Int J Mol Sci ; 11(12): 4782-95, 2010.
Article in English | MEDLINE | ID: mdl-21614173

ABSTRACT

Soy isoflavones, found in soybean and soybean products, have been reported to possess many physiological activities such as antioxidant activity, inhibition of cancer cell proliferation, reduction of cardiovascular risk, prevention of osteoporosis and alleviation of postmenopausal syndrome. In our previous study, soy isoflavone extract ISO-1 (containing 12 soy isoflavones) from soybean cake was demonstrated to prevent skin damage caused by UVB exposure. In this study, soy isoflavone extract from soybean cake was further purified and evaluated for the protective effects on UVB-induced damage. The results revealed that Fraction 3, which contains the aglycone group (daidzein, genistein and glycitein) and acetylglucoside group (acetyldaidzin, acetylgenistin and acetylglycitin) of soy isoflavones, could inhibit UVB-induced death of human keratinocytes and reduce the level of desquamation, transepidermal water loss (TEWL), erythema and epidermal thickness in mouse skin. Furthermore, topical application of Fraction 3 increased the activity of catalase and suppressed cyclooxygenase-2 (COX-2) and proliferating cell nuclear antigen (PCNA) expression in mice exposed to UVB. In addition, in comparison with ISO-1 and genistein, the Fraction 3 possessed much greater protective effects on both UVB-induced oxidative stress and keratinocyte death than other fractions. Therefore, the soy isoflavone extract Fraction 3 from soybean cake is a desirable anti-photoaging agent for skin care.


Subject(s)
Glycine max/chemistry , Isoflavones , Skin Aging , Skin/metabolism , Ultraviolet Rays/adverse effects , Animals , Catalase/metabolism , Cyclooxygenase 2/metabolism , Female , Humans , Isoflavones/chemistry , Isoflavones/isolation & purification , Isoflavones/pharmacology , Mice , Mice, Inbred ICR , Mice, Nude , Proliferating Cell Nuclear Antigen/metabolism , Skin/pathology , Skin Aging/drug effects , Skin Aging/radiation effects
15.
Metabolism ; 59(6): 780-6, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20005535

ABSTRACT

Impaired insulin secretion (ISEC) has been recognized as one of the most important pathophysiologies of type 2 diabetes mellitus. There are 2 phases of ISEC: the first phase (first ISEC) and second phase (second ISEC). This study aimed to evaluate the 2 phases of ISEC in newly diagnosed type 2 diabetes mellitus patients. Fifty-two drug-naive type 2 diabetes mellitus patients were given 2 tests: a modified low-dose graded glucose infusion (M-LDGGI) and frequent sample intravenous glucose tolerance test. The M-LDGGI is a simplified version of the Polonsky method. Two stages of intravenous infusion of glucose with different rates were given, starting from 2 mg/(kg min) and then followed by 6 mg/(kg min). Each stage was maintained for 80 minutes. The results were interpreted as the slope of the changes of plasma insulin against the glucose levels. The slope of these curves was regarded as the second ISEC and used as the criterion for grouping-the responders and nonresponders. The responders are older and had higher body mass index and log (homeostasis model assessment of beta-cell function) (log HOMA-beta) but lower fasting plasma glucose and hemoglobin A(1c) (HbA(1c)) than the nonresponders. Significant correlations were only noted between the second ISEC and first ISEC (r = 0.278, P = .046) and between the second ISEC and log HOMA-beta (r = 0.533, P = .000). Correlation between different parameters and HbA(1c) was also evaluated. Only second ISEC and log HOMA-beta were correlated significantly with HbA(1c) (r = -0.388, P = .015 and r = -0.357, P = .026, respectively). In type 2 diabetes mellitus, subjects with higher second ISEC are older and have higher body mass index. At the same time, second ISEC is the most important factor for determining glucose levels in naive Chinese type 2 diabetes mellitus patients. The first and second ISECs were only modestly correlated, which indicated that the deterioration of these 2 phases was not synchronized. Finally, we also recommend using the M-LDGGI for quantifying second ISEC. This practical method could be done in many centers without difficulty.


Subject(s)
Diabetes Mellitus, Type 2/metabolism , Insulin/metabolism , Adult , China , Female , Glucose , Glucose Tolerance Test , Glycated Hemoglobin/metabolism , Humans , Infusions, Intravenous , Insulin Resistance , Male , Middle Aged
16.
Acta Diabetol ; 47(1): 65-71, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19238313

ABSTRACT

Components of metabolic syndrome (MetS) have been associated with several inflammatory factors, including white blood cell count (WBCC). In the present study, the relationships between WBCC and aspects of MetS in young adolescents were investigated. We enrolled 596 participants (328 males and 268 females) from 10 to 13 years of age and with normal WBCC in this study. They were divided into four quartiles according to WBCC (WBCC1-4, from lowest to highest WBCC). The mean values of MetS components for each group were compared in males and females separately. Multivariate linear regression analysis between the WBCC and the components of MetS after adjusted for age and body mass index (BMI) were also evaluated. In the male group, the BMI of WBCC1 and WBCC2 was significantly lower than WBCC4. The total cholesterol and low-density lipoprotein-cholesterol (LDL-C) of WBCC2 were significantly higher than WBCC1 and WBCC4. Triglyceride (TG) levels of WBCC1 were significantly lower than WBCC3 and WBCC4, and TG levels of WBCC2 were significantly lower than WBCC4. Alternatively, the BMI of WBCC1 and WBCC2 were significantly lower than WBCC3 in the female group. Finally, the TG and fasting plasma glucose (FPG) levels of WBCC1 were significantly lower than WBCC3 or WBCC4, respectively. After multivariate linear regression, WBCC was positively correlated to BMI and TG, but negatively correlated to FPG in males whereas in young adolescent females, WBCC was positively correlated to BMI and FPG. In conclusion BMI was positively correlated with WBCC in young adolescent females and males. Thus, BMI is the most important component of MetS in this age group. In addition, TG levels in males and FPG in females were significantly related to WBCC. These findings could be regarded an early indication for the future development of full-blown MetS or cardiovascular diseases.


Subject(s)
Leukocyte Count , Metabolic Syndrome/epidemiology , Adolescent , Blood Pressure , Body Mass Index , Child, Preschool , Cross-Sectional Studies , Female , Humans , Lipids/blood , Male , Medical History Taking , Metabolic Syndrome/blood , Sex Characteristics , Surveys and Questionnaires
17.
Metabolism ; 57(11): 1615-21, 2008 Nov.
Article in English | MEDLINE | ID: mdl-18940402

ABSTRACT

Diabetic patients with metabolic syndrome (MetS) have higher lifetime risks for cardiovascular disease, especially in early-onset type 2 diabetes mellitus (EODM). Increased insulin resistance (IR) and impaired insulin secretion are important pathophysiologies in diabetic patients. Therefore, the effects of MetS on IR and insulin secretion in EODM were investigated. Forty-eight EODM (mean age, 22.8 +/- 0.6 years) patients were enrolled in this study. Two grouping criteria were used: the first was whether the patient had MetS or not (MetS+ or Met-, with 31 and 17 patients, respectively); and the second was the number of MetS components each group had, that is, MetS (1,2) with 1 to 2, MetS (3) with 3, and MetS (4,5) with 4 to 5 components (17, 17, and 14 patients in each group, respectively). A frequently sampled intravenous glucose tolerance test was performed to measure insulin sensitivity, glucose sensitivity, acute insulin response after glucose load, and disposal index. Severe IR was noted with both homeostasis model assessment and frequently sampled intravenous glucose tolerance test both in MetS+ and MetS-. However, significantly higher acute insulin response after glucose load and disposal index were noted in MetS+ and MetS (4,5) than in Met-, MetS (1,2), and MetS (3), respectively. Early-onset type 2 diabetes mellitus patients with MetS had similar IR to those without MetS. This may be due to early deterioration of insulin action in these subjects. In addition, insulin secretion was higher in subjects with more MetS components, suggesting that EODM patients with MetS had better preserved ability of beta-cell compensation for IR than those without MetS.


Subject(s)
Blood Glucose/metabolism , Diabetes Mellitus, Type 2/metabolism , Insulin Resistance , Insulin/metabolism , Metabolic Syndrome/metabolism , Adult , Body Mass Index , Cohort Studies , Female , Humans , Insulin Secretion , Insulin-Secreting Cells/physiology , Male
18.
J Clin Gastroenterol ; 40(6): 551-4, 2006 Jul.
Article in English | MEDLINE | ID: mdl-16825939

ABSTRACT

GOALS: This study was conducted to explore the association between nonalcoholic fatty liver disease and glucose metabolism as well as insulin resistance using the homeostasis model assessment method (HOMA). STUDY: From July 2003 to June 2004, 23 patients with ultrasound-proved fatty liver and either normal (10 patients) or abnormal (13 patients) serum aminotransferase levels were enrolled. Blood tests included a routine biochemistry, a 75-g glucose oral glucose tolerance test (OGTT) with blood sampled at 30-minute intervals during a 120-minute period. Fasting and 120-minute serum leptin, insulin, and C-peptide concentrations were also measured. RESULTS: Using the Mann-Whitney U test, significant differences were found in gamma glutamyl transpeptidase (28.6+/-7.9 vs. 65.1+/-65.9 U/L, P=0.008), fasting insulin (FI) (13.11+/-7.53 vs. 31.76+/-42.95 muU/mL, P=0.02), fasting C-peptide (3.82+/-3.00 vs. 2.17+/-0.43 ng/mL, P=0.01), fasting leptin (10.34+/-4.05 vs. 24.27+/-24.97 ng/mL, P=0.01), HOMA-IR (3.34+/-1.06 vs. 8.81+/-13.18, P=0.02), and HOMA beta-cell function (120.32+/-52.50 vs. 242.20+/-247.29, P=0.02) between normal and abnormal ALT/AST function groups. From the 75-g OGTT, no significant difference of plasma glucose was noted at 0, 30, 60, and 90 minutes but significant change was noted in 120-minute plasma glucose (99.3+/-21.5 vs. 131.4+/-27.3 mg/dL, P=0.004) of 2 groups. CONCLUSIONS: In conclusion, patients with fatty liver proved by ultrasound sonography might be at high risk of developing type 2 diabetes, especially when they had elevated liver enzymes. OGTT is warranted for the early diagnosis of these high risk patients.


Subject(s)
Alanine Transaminase/blood , Aspartate Aminotransferases/blood , Fatty Liver/blood , Hyperglycemia/blood , Postprandial Period , Adult , Biomarkers/blood , C-Peptide/blood , Fatty Liver/complications , Fatty Liver/diagnostic imaging , Female , Food Deprivation , Glucose Tolerance Test , Homeostasis , Humans , Hyperglycemia/complications , Hyperglycemia/pathology , Insulin/blood , Leptin/blood , Liver Function Tests , Male , Metabolic Syndrome/blood , Ultrasonography
20.
J Chin Med Assoc ; 66(3): 155-9, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12779035

ABSTRACT

BACKGROUND: The aim of this study is to compare the clinical responses between Mixtard 50 HM (premixed insulin with 50% regular insulin (RI) and 50% neutral protamine Hagedom (NPH)) and Mixtard 30 HM (premixed insulin with 30% RI and 70% NPH) among type 2 diabetic patients. The acceptability of NovoPen 3 and traditional syringe was also evaluated among these patients. METHODS: Twenty-six patients were injected with Mixtard 30 HM initially using traditional syringe, which was switched to Mixtard 50 HM eight weeks later. When the switch commenced, patients were randomly assigned to two groups. One group used traditional syringe and the other used NovoPen 3. Blood glucoses were measured before breakfast, before lunch and at bedtime for two days in a week by patients themselves. Hemoglobin A(1c)(HbA(1c)) was checked at week 8 and week 16. At the end of the trial, patients completed 1 questionnaires regarding their acceptability of NovoPen 3. RESULTS: There was no statistical difference in mean blood glucose levels measured before breakfast, before lunch, or at bedtime, or in HbA(1c), between Mixtard 30 HM and Mixtard 50 HM treatment periods. However, blood glucose after breakfast declined more in Mixtard 50 HM treatment period than in Mixtard 30 HM treatment period. Up to 96.2% of the study subjects reported that NovoPen 3 was more convenient in use than traditional syringe. CONCLUSIONS: Blood glucose declined more from pre-breakfast level to pre-lunch level when patients used Mixtard 50 HM instead of Mixtard 30 HM. We suggest that Mixtard 50 HM is more appropriate for post-breakfast hyperglycemic diabetic patients. NovoPen 3 results in a similar clinical glycemic response but is better accepted by the patients than conventional syringe.


Subject(s)
Diabetes Mellitus, Type 2/drug therapy , Insulin/administration & dosage , Adult , Aged , Blood Glucose/analysis , Female , Glycated Hemoglobin/analysis , Humans , Insulin/blood , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...